SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Biocept, Inc. BIOC NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Biocept, Inc. (BIOC) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $0.43. It has a SharesGrow Score of 25/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $26M, +154%/yr average growth. Net income is $32M (loss), growing at -307.3%/yr. Net profit margin is -124.1% (negative). Gross margin is -10% (+88.6 pp trend).

Balance sheet: total debt is $12M against $9M equity (Debt-to-Equity (D/E) ratio 1.37, moderate). Current ratio is 2.97 (strong liquidity). Debt-to-assets is 39.2%. Total assets: $31M.

Analyst outlook: 1 / 3 analysts rate BIOC as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 15/100 (Fail), Future 20/100 (Fail), Income 10/100 (Fail).

BIOC SharesGrow Score Overview

31/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 15/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BIOC

No analyst coverage available for this stock.

BIOC: +154%/yr revenue is, -307.3%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet BIOC: Debt-to-Equity (D/E) ratio 1.37 (moderate), Current ratio is 2.97 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

BIOC: Gross margin is -10% (+88.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 15/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 3 analysts rate BIOC as buy (33%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

BIOC: Net profit margin is -124.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.4349-0.4349

Volume572.52K

Market Cap$450.79K

Beta (1Y)0.60

Share Statistics

EPS (TTM)-56.78

Shares Outstanding$565.13K

IPO Date2014-02-05

Employees50

CEODarrell Taylor

Financial Highlights & Ratios

Revenue (TTM)$25.86M

Gross Profit$-2.58M

EBITDA$-30.33M

Net Income$-32.09M

Operating Income$-31.98M

Total Cash$12.9M

Total Debt$12.11M

Net Debt$-788K

Total Assets$30.87M

Price / Earnings (P/E)-0

Price / Sales (P/S)0.02

Analyst Forecast

Rating ConsensusHold

Analysts Covering3

Buy 33% Hold 67% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS09072V6002

Price Chart

BIOC

Biocept, Inc. ↗ · NASDAQ Capital Marke

Healthcare • Medical - Diagnostics & Research

People Also View

Actinium Pharmaceuticals, Inc.

Onconova Therapeutics, Inc.

Aytu BioPharma, Inc.

Diffusion Pharmaceuticals Inc.

Eli Lilly and Company

Johnson & Johnson

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message